Guardant Health, Inc. (NASDAQ:GH) Stake Lifted by GAMMA Investing LLC

GAMMA Investing LLC increased its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 11,765.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,679 shares of the company's stock after purchasing an additional 17,530 shares during the quarter. GAMMA Investing LLC's holdings in Guardant Health were worth $7,530,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of GH. NewEdge Advisors LLC raised its holdings in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock valued at $377,000 after buying an additional 391 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares during the period. Jones Financial Companies Lllp increased its position in shares of Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after acquiring an additional 817 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after acquiring an additional 929 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

GH traded down $0.01 on Thursday, reaching $49.02. 1,250,531 shares of the company's stock were exchanged, compared to its average volume of 2,126,758. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $52.92. The company's 50 day moving average is $43.39 and its 200-day moving average is $41.36. The company has a market cap of $6.07 billion, a price-to-earnings ratio of -13.77 and a beta of 1.37.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share. The business's quarterly revenue was up 20.8% compared to the same quarter last year. Sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. The Goldman Sachs Group raised their price target on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stephens reiterated an "overweight" rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Stifel Nicolaus lifted their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Finally, Raymond James reissued an "outperform" rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Guardant Health has an average rating of "Buy" and an average target price of $53.29.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 1,680 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $50.00, for a total transaction of $84,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,060 shares of the company's stock, valued at approximately $109,353,000. This represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 226,516 shares of company stock worth $11,226,549 over the last quarter. 6.10% of the stock is owned by corporate insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.